M
Michael Molls
Researcher at Ludwig Maximilian University of Munich
Publications - 53
Citations - 1217
Michael Molls is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Radiation therapy & Breast cancer. The author has an hindex of 18, co-authored 53 publications receiving 1154 citations.
Papers
More filters
Journal ArticleDOI
Update of human spinal cord reirradiation tolerance based on additional data from 38 patients
TL;DR: Based on these updated results, the risk of RM appears small after < or =135.5 Gy(2), and the influence of very steep dose gradients from stereotactic and intensity-modulated approaches (i.e., a more complex volume-effect) requires further evaluation.
Journal ArticleDOI
Current status of angiogenesis inhibitors combined with radiation therapy
TL;DR: Early results suggest that acute toxicity is acceptable, planned surgery after such treatment is feasible, and that further evaluation of such combined modality treatment is warranted.
Journal ArticleDOI
Fatigue in patients with adjuvant radiation therapy for breast cancer: long-term follow-up
TL;DR: Fatigue 2.5 years after adjuvant radiation therapy (RT) in patients with localized breast cancer did not increase above baseline levels before RT in conservatively operated breast cancer patients.
Book
Blood perfusion and microenvironment of human tumors : implications for clinical radiooncology
Michael Molls,Peter Vaupel +1 more
TL;DR: This is a summary of knowledge on blood perfusion and the microenvironment of human tumours, designed to enable the reader to gain a deeper insight into the physiological components of malignant tumours.
Journal ArticleDOI
Changes in tumor oxygenation during combined treatment with split-course radiotherapy and chemotherapy in patients with head and neck cancer
TL;DR: The decrease in the tumor oxygenation status at doses of 30 and 70 Gy are important findings because they are in contrast to the concept of continuous improvement of the oxygenationstatus during fractionated radiotherapy.